Patient-reported outcomes and radiographic progression in patients with rheumatoid arthritis in sustained remission versus low disease activity
Authors' conclusion
Patients with RA who reach sREM in the first year have better HRQoL and function, and less pain, fatigue and productivity loss in the years thereafter, compared with patients with RA who are in sLDA or AD in the first year.
Study context
- Population
- Patients with rheumatoid arthritis (RA) from the treatment in the Rotterdam Early Arthritis CoHort trial (treat-to-target aiming for LDA, Disease Activity Score (DAS) ≤2.4)
- Participants
- 173 / 142 / 59
- Comparison
- Sustained low disease activity (sLDA) or active disease (AD) vs sustained remission (sREM) in the first year after diagnosis
- sREMn = 173reference
- sLDAn = 142
- ADn = 59
- Primary endpoint
- Patient-reported outcomes (PROs) (pain, fatigue, functional impairment, HRQoL, health status, productivity loss) over 5 years; radiographic progression (mTSS) over 2 years
- Follow-up
- 5 years
Methodological detailsmulticentre, stratified, single-blinded, treat-to-target
- Multicentre
- Stratified
- Single-blinded
- Treat-to-target
Primary result
As reported in the abstract
PROs during follow-up, sLDA vs sREM
sLDA vs sREMDifference, units (95% CI)
Pain (0-10 Likert), higher
0.90(0.52–1.27)
Fatigue (VAS), higher
12.10(7.27–16.92)
Functional impairment (HAQ-DI), higher
0.28(0.17–0.39)
sLDA vs sREMDifference (95% CI)
Productivity loss (0%-100%), higher
7.76%(2.76–12.75)
- Physical health-related quality of life (HRQoL) (SF-36 PCS), lower
- difference 4.42 units (95% CI −6.39 to −2.45)
- Mental HRQoL (SF-36 MCS), lower
- difference 2.95 units (95% CI −4.83 to −1.07)
- Health status (EQ-5D-3L), lower
- difference 0.06 units (95% CI −0.09 to −0.03)
Further findings
Radiographic progression (modified Total Sharp Score (mTSS)) · 2 years
- No differences in mTSS between groups
Original publication
Patient-reported outcomes and radiographic progression in patients with rheumatoid arthritis in sustained remission versus low disease activity. RMD Open. Published 20 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →